ONDO - Ondo InsurTech PLC
Executive Summary
Ondo InsurTech PLC (ONDO) is a UK-listed software company specialising in LeakBot, a connected water-leak detection device and claims-prevention service marketed to UK and US insurers. The company occupies a niche position in insurance technology, with its hardware-and-software solution positioned as a tool for insurers to reduce water-damage claims rather than a general consumer product. Its market position is that of a small-cap, single-product vendor dependent on a limited number of insurer partnerships.
The investment case requires continued US deployment momentum, conversion of the existing Selective Insurance contract into recurring revenue, and progress towards EBITDA positivity. The FY2026 results released on 29 July 2026 and the May 2026 expansion of the all-employee Share Incentive Plan are the most recent operational touchpoints, with the next scheduled milestone being the interim results for the half-year ending March 2026. The primary risk is that the company has continued to report operating losses and remains cash-burn dependent, leaving the equity exposed to further dilutive fundraisings or convertible issuance.
OPPORTUNISTIC BUY. Conviction Score: 59/100. A confirmed return to revenue growth at the run-rate implied by the FY2026 results, accompanied by a clear path to narrowed operating losses, would upgrade the view towards a higher-conviction rating; conversely, a further capital raise at a discount to the prevailing share price, or evidence of stalled US deployments, would degrade the call.
Business Model
Ondo generates revenue principally from leasing or selling LeakBot units to home insurers, who in turn provide the device to policyholders at no direct cost as a claims-prevention benefit. The hardware is paired with a software and analytics service that monitors water-flow patterns and alerts the policyholder, and where appropriate the insurer, to slow leaks before they escalate into damaging events. The company has described the leakage-detection algorithm and the insurer-distribution channel as the basis of its competitive offering; this is a niche proposition rather than a broad consumer brand.
In the FY2026 results announced on 29 July 2026, the company reported revenue of GBP 4.6 million, up 20% year-on-year, with recurring revenue of GBP 3.8 million, up 51% and representing 83% of the total mix. The recurring-revenue share is the key business-model metric: it indicates that the majority of income is now derived from ongoing service-style contracts rather than one-off hardware sales, which materially improves the visibility of forward revenue. Hardware unit shipments and pilot expansions continue to drive the remaining non-recurring component.
The competitive moat rests on three identifiable elements: the proprietary leak-detection algorithm and the data set of monitored events accumulated through the existing UK customer base; the entrenched distribution relationship with insurers, which is slow to replicate; and the regulatory positioning of LeakBot as a loss-prevention tool, which aligns insurer incentives. None of these is structurally insurmountable, but they do create switching costs for insurer partners once LeakBot is embedded into a policyholder benefit programme. The primary vulnerability in the model is the small number of insurer counterparties, which concentrates revenue risk into a handful of contracts.
Financial Snapshot
Recent Catalysts
[29 July 2026] - Ondo InsurTech PLC released its Final Results for the year ending March 2026, reporting revenue of GBP 4.6 million (up 20%) and recurring revenue of GBP 3.8 million (up 51%), with recurring revenue representing 83% of total revenue. Source: Ondo InsurTech PLC results announcement (RNS via Investegate / company website).
[6 May 2026] - Ondo InsurTech announced an expansion of its all-employee Share Incentive Plan, with directors participating in purchases alongside other staff; the SIP framework is administered by Fiduchi Trustees Limited (UK). Source: Insurance Nerds Editorial Team; Investegate RNS announcement.
[1 May 2026] - Fiduchi Trustees Limited (UK), acting as the SIP Trustee, notified Ondo InsurTech of market purchases of ordinary shares under the Share Incentive Plan, providing a small but observable insider-aligned buying signal. Source: Investegate RNS announcement; ADVFN company news.
[5 May 2026] - Press reporting noted that Ondo InsurTech shares had set a new 52-week low, with the stock trading as low as 3.50p and closing at 3.85p on elevated volume. Source: Stock Observer (www.thestockobserver.com).
[29 April 2026] - Earlier press coverage had already flagged a new twelve-month low at 3.50p / 3.73p on volume above 1.3 million shares, reflecting continued share-price weakness into the spring reporting window. Source: Daily Political (www.dailypolitical.com).
Thesis Evaluation
Bull Case (25% weight)
US deployment metrics continue to scale, the Selective Insurance contract converts into a sustained recurring-revenue contributor, and the FY2026 trajectory of 20% revenue growth and 51% recurring-revenue growth is maintained or accelerated. LeakBot adoption broadens across the US insurer pipeline, moving the business towards the EBITDA-positive milestone management has signalled for FY26. In this scenario, the share price recovers materially from the current 7.9p level towards a twelve-month target of 18p.
Base Case (50% weight)
The most likely outcome is that FY2026's 20% revenue growth and 83% recurring-revenue mix are broadly sustained, Selective delivers as contracted, but operating losses of around the GBP 6.4m level disclosed in recent filings continue to absorb cash and require either a small capital raise or convertible support. The share price oscillates around the current 7.9p area as the market weighs the recurring-revenue story against the funding dependence. The twelve-month base-case target is 8.5p.
Bear Case (25% weight)
A combination of a further dilutive capital raise at a discount to the prevailing share price, slower-than-expected US cohort maturation, and continued margin compression from hardware deployment costs keeps operating losses elevated and forces a re-rating lower. Selective contract economics disappoint or a competing loss-prevention solution gains traction with US insurers. In this scenario, the share price revisits and breaks below the 3.50p 52-week low towards a twelve-month target of 2.5p.
Key Risks
- Funding dependence and dilution: The company has reported continued operating losses and remains cash-burn dependent, exposing the equity to further dilutive capital raises or convertible issuance. Estimated probability: 60%. Impact: severe.
- Customer concentration: Revenue is concentrated across a small number of insurer partners, including the Selective Insurance contract, so any single contract loss or renegotiation materially affects the revenue base. Estimated probability: 35%. Impact: severe.
- US deployment execution risk: Forward growth depends on the US cohort scaling at a pace consistent with the FY2026 20% revenue uplift; slower adoption would push out the path to EBITDA positivity. Estimated probability: 45%. Impact: moderate.
- Margin compression from hardware costs: Device deployment costs and the non-recurring hardware component of revenue can compress unit economics if hardware volumes grow faster than recurring-service volumes. Estimated probability: 40%. Impact: moderate.
- Share price volatility and liquidity: The 52-week range of 2.8p to 35p and the spring 2026 series of new 52-week lows on elevated volume indicate materially elevated price volatility and thin liquidity for an AIM-scale stock. Estimated probability: 70%. Impact: moderate.
- Competitive substitution in loss-prevention: Competing smart-water or leak-detection propositions reaching US insurers could erode the niche position LeakBot currently occupies. Estimated probability: 25%. Impact: moderate.
Who Should Own It / Avoid It
Ideal for: High-risk-tolerance investors with a multi-year horizon (minimum 24 months) who can tolerate small-cap, loss-making, single-product exposure and are comfortable with the prospect of further dilutive raises. The position is appropriate for a portfolio where ONDO represents a satellite, not a core, allocation and where the investor can underwrite the possibility of a drawdown towards the 52-week low of 2.8p without forced selling. A genuine interest in UK insurtech and a willingness to monitor RNS flow for contract updates and interim results is essential.
Avoid if: Investors with a low tolerance for capital loss, those requiring current income (no dividend is being forecast), or those restricted to profitable, cash-generative businesses should not hold ONDO. Investors with a short time horizon, those unable to absorb a further dilutive raise, and anyone benchmarking against broad-market indices should also avoid the position, as should investors who cannot tolerate the share-price volatility shown by the 2.8p to 35p 52-week range.
Recommendation
OPPORTUNISTIC BUY - 59/100. The tier reflects a balance between the genuine recurring-revenue traction visible in FY2026 (83% of revenue, up 51%) and the unresolved funding dependence, ongoing operating losses, and small-cap volatility that materially cap upside. The call would be upgraded towards a higher-conviction rating on confirmed US deployment milestones, a clear narrowing of operating losses, or evidence of customer diversification beyond Selective. The call would be downgraded on a discounted capital raise, a Selective contract disruption, or a stalling of the 20% revenue-growth trajectory. At the current price of 7.90p the shares trade above our buy ceiling of 4.50p: the thesis is credible but the price is not - new positions only below that level.
The probability-weighted value across our three scenarios is 9.38p, 19% above the current price of 7.90p - the market has not yet priced our probability-weighted view. Levels below are derived from the scenario targets and probabilities above, not from percentage offsets to today's price.
below 4.50p - below this level the upside to the base-case target (8.50p) is at least 2x the downside to the bear case (2.50p), the minimum risk/reward we require before committing new capital.
between 4.50p and 8.50p - the base case is not yet fully priced, so existing holders are paid to wait, but new money gets no margin of safety in this zone.
above 8.50p - at this level the base case is fully reflected in the price and anything beyond it is paying for a bull scenario we weight at 25%.
if A loss or material downsizing of the Selective Insurance contract, a further dilutive raise at a discount to the prevailing share price, or revenue growth decelerating below the FY2026 20% rate on a like-for-like basis, regardless of price - the bear target of 2.50p is the backstop, not an arbitrary percentage stop.
Conviction Trend
Latest conviction: 29/100. Trend versus prior report: Initiation.
| Report date | Conviction |
|---|---|
| 2026-08-14 | 29 |
Sources
Market data: DYOR HQ proprietary market data workflow.
Public sentiment and news flow: Public news flow including company press releases distributed via Regulatory News Service and Investegate, the company's investor relations website (ondoplc.com), financial news commentary on the share price including Stock Observer and Daily Political, and reference coverage from Simply Wall St for background financial context.
Primary source types: Regulatory announcements via RNS (Share Incentive Plan Purchase, FY2026 final results), company investor relations materials including the results centre and annual report PDF, third-party verified financial news wires, and aggregator commentary referenced for background colour only.
Key sources
- Ondo InsurTech 2026 Company Profile: Stock Performance & Earnings | PitchBook
- Ondo InsurTech Plc Reports Earnings Results for the Full Year Ended March 31, 2026
- REG - Ondo InsurTech PLC - Share Incentive Plan Purchase - TradingView News
- Ondo InsurTech PLC Share Incentive Plan Purchase - ADVFN
- Ondo InsurTech Plc (ONDO.L) Stock Price, News, Quote & History - Yahoo Finance
- Ondo InsurTech Share Price, Forecast & Financials (LON:ONDO) | Stockopedia
- Ondo InsurTech Plc Share Price (ONDO) - Stock London S.E. - MarketScreener India
- Ondo Insurtech primed and ready for growth after landmark deal | LSE:ONDO
- Ondo Insurtech contract win
- ONDO INSURTECH PLC overview - Find and update company information - GOV.UK
Data correct as of 2026-08-14